Clinical trial NCT04937153: GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies
Official title: Open-label, Dose-escalation Trial to Evaluate the Safety and Pharmacokinetics of GEN1046 in Japanese Subjects With Advanced Solid Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Solid Tumor
Lead sponsor: Genmab
Sponsor class: INDUSTRY
Collaborators: name: BioNTech SE
First posted: 2021-06-23
Enrollment: 18
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: The starting dose is 15 mg administered as a flat dose. Dose escalation steps are based on safety data.
Primary purpose: TREATMENT

Brief summary: The primary objective of the study is to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and pharmacokinetics (PK) of acasunlimab (also known as GEN1046) administered as monotherapy or in combination with pembrolizumab in Japanese study participants with malignant solid tumors.


Eligibility criteria: Key Inclusion Criteria:

* Participant must have a histologically-confirmed non-central nervous system (CNS) solid tumor that is metastatic or unresectable and for whom there is no available standard therapy likely to confer clinical benefit; or a participant who is not a candidate for such available therapy and for whom, in the opinion of the investigator, experimental therapy with acasunlimab or acasunlimab in combination with pembrolizumab may be beneficial.
* Asian race and Japanese ethnicity.
* Have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
* Have Eastern Cooperative Oncology Group (ECOG) 0-1.
* Have an acceptable hematological status.
* Have acceptable liver function.
* Have an acceptable coagulation status.
* Have acceptable renal function.
* Should provide a tumor tissue sample (formalin-fixed paraffin-embedded \[FFPE\] blocks/slides) from archival tissue or fresh biopsy collected before C1D1, preferably derived from advanced disease stage.

Key Exclusion Criteria:

* Have uncontrolled intercurrent illness, including but not limited to:

  * Ongoing or active infection requiring intravenous treatment with anti-infective therapy, or any ongoing systemic inflammatory condition requiring further diagnostic work-up or management during screening.
  * Symptomatic congestive heart failure (Grade III or IV as classified by the New York Heart Association), unstable angina pectoris or cardiac arrhythmia.
  * Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg, despite optimal medical management.
  * Ongoing or recent evidence of autoimmune disease.
  * History of irAEs that led to prior checkpoint treatment discontinuation.
  * Prior history of myositis, Guillain-Barré syndrome, or myasthenia gravis of any grade.
  * History of chronic liver disease or evidence of hepatic cirrhosis.
  * Evidence of interstitial lung disease.
  * History of non-infectious pneumonitis that has required steroids or currently has pneumonitis.
  * History of organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of trial treatment.
  * Serious, non-healing wound, skin ulcer (of any grade), or bone fracture.
* Any history of intracerebral arteriovenous malformation, cerebral aneurysm, new (younger than 6 months) or progressive brain metastases or stroke.
* Prior therapy:

  * Radiotherapy: Radiotherapy within 14 days prior to the first dose of trial treatment. Palliative radiotherapy will be allowed.
  * Treatment with an anti-cancer agent (within 28 days or after at least 5 half-lives of the drug, whichever is shorter), prior to trial treatment administration.
* Toxicities from previous anti-cancer therapies that have not adequately resolved.

Note: Other protocol specified inclusion/exclusion criteria may apply.

Primary outcomes:
measure: Number of Participants with Dose limiting Toxicities (DLTs)
timeFrame: During first cycle (Cycle length=21 days) in each cohort
measure: Number of Participants with Adverse Events (AEs)
timeFrame: From first dose date up to end of the safety follow up period, 90 days after last dose
measure: Area under the concentration time curve (AUC) of Acasunlimab
timeFrame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)
measure: Maximum (Peak) Plasma Concentration (Cmax) of Acasunlimab
timeFrame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)
measure: Time to Reach Cmax (Tmax) of Acasunlimab
timeFrame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)
measure: Plasma Trough (Pre-dose) Concentrations (Cthrough) of Acasunlimab
timeFrame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)
measure: Elimination half-life (t 1/2) of Acasunlimab
timeFrame: Predose and postdose at multiple timepoints of each cycle (Cycle length=21 days)
Secondary outcomes:
measure: Number of Participants with Anti-Drug Antibody (ADA) to Acasunlimab
timeFrame: Up to 2 years
Other outcomes:
Locations:
city: Chiba
country: Japan
facility: National Cancer Center East
city: Tokyo
country: Japan
facility: National Cancer Center Hospital
Study officials:
affiliation: Genmab
name: Study Official
role: STUDY_DIRECTOR
References: